Related Experiment Video
Updated: Aug 5, 2026
08:50
Prostaglandin Extraction and Analysis in Caenorhabditis elegans
Published on: June 25, 2013
Exercise, Prostaglandin E2, and Cardiometabolic Health: From Molecular Signaling to Systemic Adaptation
Joseph Mannozzi1,2,3, Mike M Ravn Pedersen3,4, Shaheen Y Bhat3,4
1Cardiovascular Medicine, Henry Ford Health, Detroit, MI 48202, USA.
Cells
|July 27, 2026
Summary
Exercise influences cardiometabolic health through molecular mediators like Prostaglandin E2 (PGE2). This review explores PGE2
Area of Science:
- Exercise physiology
- Molecular biology
- Cardiovascular science
Background:
- Exercise is a vital therapy for cardiometabolic disorders.
- Molecular links between exercise and metabolic adaptations are not fully understood.
- Prostaglandin E2 (PGE2) is a lipid mediator involved in inflammation and metabolic regulation.
Purpose of the Study:
- To review the role of Prostaglandin E2 (PGE2) in exercise.
- To examine PGE2's influence on cardiometabolic health and disease.
Main Methods:
- Literature review of existing studies on PGE2 and exercise.
- Synthesis of evidence on PGE2 biosynthesis and signaling pathways.
- Analysis of PGE2's role in metabolic and cardiovascular adaptations.
Main Results:
- PGE2 emerges as a key regulator of exercise-induced adaptations.
- Evidence links PGE2 to inflammation, vascular function, and glucose-lipid homeostasis.
- PGE2 signaling is implicated in mitochondrial remodeling during physical activity.
Conclusions:
- PGE2 is a significant molecular mediator of exercise benefits.
- Understanding PGE2 pathways can inform therapeutic strategies for cardiometabolic diseases.
- Further research into PGE2 signaling in exercise is warranted.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...